MUCCINI, CAMILLA
 Distribuzione geografica
Continente #
NA - Nord America 246
EU - Europa 220
AS - Asia 59
AF - Africa 9
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
SA - Sud America 1
Totale 543
Nazione #
US - Stati Uniti d'America 243
SE - Svezia 106
IT - Italia 72
CN - Cina 30
FI - Finlandia 22
DE - Germania 9
AU - Australia 7
AE - Emirati Arabi Uniti 6
IN - India 6
SG - Singapore 6
NG - Nigeria 5
CH - Svizzera 4
PH - Filippine 4
CA - Canada 3
HK - Hong Kong 3
MD - Moldavia 3
IR - Iran 2
NL - Olanda 2
PK - Pakistan 2
TN - Tunisia 2
ZA - Sudafrica 2
BE - Belgio 1
EC - Ecuador 1
EU - Europa 1
FR - Francia 1
Totale 543
Città #
New York 49
Ashburn 43
Shanghai 30
Helsinki 22
Lawrence 22
Princeton 22
Milan 14
Washington 9
Melbourne 6
Sharjah 6
Lagos 5
Rome 5
Seattle 5
Vittoria 5
Boston 4
Pune 4
Quezon City 4
Vauderens 4
Angera 3
Cambridge 3
Chisinau 3
Singapore 3
Bibiana 2
Borås 2
Catania 2
Cormano 2
Genoa 2
Kai Yi Wan 2
Lahore 2
Los Angeles 2
Montreal 2
Naples 2
Nicolosi 2
Padova 2
Segrate 2
Torre Del Greco 2
Verona 2
Viterbo 2
Amsterdam 1
Central 1
Delhi 1
Durban 1
Faenza 1
Falkenstein 1
Gent 1
Lainate 1
Legnano 1
Marseille 1
Messina 1
Paliano 1
Pavia 1
Pretoria 1
Quito 1
Recco 1
San Sperate 1
Sydney 1
Venlo 1
Totale 322
Nome #
Evaluation of HIV reservoir in specific populations: people with a multi-drug resistant virus or a viral coinfection 95
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 41
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 30
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 27
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 25
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 22
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 22
Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression who switched to a different antiretroviral regimen 20
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 19
Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy 19
Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study) 19
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 19
Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance 18
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium 18
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 17
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients 17
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 16
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 16
Western blot in treated people with HIV-1 chronic infection: frequency of negative HIV-1 pol genes 16
Homeostatic model assessment for insulin resistance index trajectories in HIV-infected patients treated with different first-line antiretroviral regimens 13
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 12
Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: A MODAt substudy 11
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 11
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium 10
Challenging management of a post-coronavirus disease 2019 invasive Aspergillus sinusitis in a person living with HIV 10
Achieving virological control in pan-resistant HIV-1 infection: A case series 9
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 9
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 7
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 7
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents 7
Risk of Cardiovascular Diseases or Mortality in People with Higher Values of HIV-1 DNA 6
Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection 6
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 6
Should we expect weight changes in people with HIV and a reported weight gain only by switching antiretroviral therapy? 5
A four-drug combination oral tablet of darunavir, cobicistat, emtricitabine, and tenofovir alafenamide for the treatment of HIV-1 infection in adults 5
Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting 4
Subclinical atherosclerosis as detected by carotid ultrasound and associations with cardiac and HIV-specific risk factors; the Archi-Prevaleat project 4
Increasing trend of transmitted integrase inhibitor resistance in a cohort of antiretroviral therapy-naive people living with HIV 4
Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV 3
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 3
Totale 628
Categoria #
all - tutte 5.667
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.667


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202120 0 0 0 4 0 9 0 5 1 0 1 0
2021/202249 0 0 0 8 1 6 4 10 8 3 2 7
2022/2023202 52 44 11 3 8 18 25 22 5 2 6 6
2023/2024356 14 16 79 30 49 71 41 38 3 15 0 0
Totale 628